The variable clinical outcomes of Multiple Myeloma (MM) patients are incompletely defined by current prognostication tools. We examined the clinical utility of high-resolution telomere length analysis as a prognostic marker in MM. Cohort stratification, using a previously determined length threshold for telomere dysfunction, revealed that patients with short telomeres had a significantly shorter overall survival (P < 0Á0001; HR = 3Á4). Multivariate modelling using forward selection identified International Staging System (ISS) stage as the most important prognostic factor, followed by age and telomere length. Importantly, each ISS prognostic subset could be further risk-stratified according to telomere length, supporting the inclusion of this parameter as a refinement of the ISS.
Despite the introduction of novel therapeutic modalities, patients with multiple myeloma (MM) display a heterogeneous clinical course, with survival ranging from a few months to over 10 years. Therefore, there is a requirement for reliable prognostic and predictive markers in this disease to allow for risk stratification and rational clinical decisionmaking. The most commonly used prognostic system in MM is the International Staging System (ISS) that is based on serum levels of both b 2 -micoglobulin and albumin (Greipp et al, 2005) . Recently the ISS has been improved upon by the inclusion of cytogenetic information to take into account the level of lactate dehydrogenase and the considerable genetic heterogeneity known to occur in this disease (Palumbo et al, 2015) . Hyperdiploidy and the loss of whole chromosome arms is frequently detected in MM, which includes, amongst others, gains of 1q in 30% of cases and the loss of 17p in 7% of cases (Walker et al, 2010) .
Short dysfunctional telomeres are susceptible to DNA repair activities that can result in chromosomal fusion and the initiation of cycles of anaphase-bridging, breakage and fusion that can drive genomic instability and clonal evolution (Artandi et al, 2000; Roger et al, 2013; Jones et al, 2014) . Telomere dysfunction has been documented in numerous haematological malignancies (Jones et al, 2012) , and is one putative mechanism that may lead to the genetic and clinical heterogeneity observed in MM (Wu et al, 2003) and may relate to changes in the 3D telomeric architecture that have been documented in MM cells (Klewes et al, 2013) . Recently, we have shown that high-resolution telomere analysis, combined with a functional definition of telomere length, can provide powerful prognostic information in several tumour types, including chronic lymphocytic leukaemia (CLL) (Lin et al, 2014) , myelodysplasia (unpublished observations) and breast cancer (Simpson et al, 2015) . Here we sought to apply these technologies to examine the prognostic utility of telomere length in MM.
Materials and methods

Patient samples and cell separation
Patient samples were collected at diagnosis, prior to treatment, through treating centres within the Heart of England (Greipp et al, 2005) .
DNA extraction and single telomere length analysis DNA was extracted from sorted cell populations using the DNeasy blood and tissue extraction kit (Qiagen, Hilden, Germany), according to the manufacturers instructions. Single telomere length analysis (STELA) at the XpYp telomere was performed as previously described (Capper et al, 2007) . A minimum of 6 polymerase chain reactions per sample were carried out for each test DNA and DNA fragments were resolved by agarose gel electrophoresis, and detected by Southern hybridisations and phosphorimaging.
Statistical methods
Statistical analysis was carried out using Prism 6Á0 (Graphpad Software Inc., La Jolla, CA, USA) and SAS version 9Á3 software (SAS Institute, Cary, NC, USA). Univariate comparisons for overall survival (OS) were conducted with the logrank test and displayed as Kaplan Meier curves. P < 0Á05 was considered significant. Analyses of time to event outcomes with respect to continuous variables or those with less than two categories, together with multivariate analyses, were performed using a Cox proportional hazard model with forward selection. P < 0Á05 was considered significant.
Results and discussion
This study used STELA of the XpYp telomere to generate telomere length profiles from unsorted bone marrow samples derived from a cohort of 61 patients with monoclonal gammopathy of undetermined significance (MGUS) and 134 patients with MM ( Fig 1A) . STELA is a high-resolution technology capable of detecting telomeres within the length ranges at which telomere fusion is known to occur Lin et al, 2014) . STELA also provides information on telomere length distributions, which relate to the clonality, replicative history and the cell purity of the tumour cell population analysed. At the individual patient level, it was apparent that the telomeres in both the MGUS and MM bone marrow samples displayed considerable length heterogeneity ( Fig 1A) , with an overall mean of the standard deviations obtained from these distributions in the MGUS cohort of 2Á23 kb and 2Á12 kb for the MM cohort. This was in contrast to a similar analysis in CLL (Lin et al, 2010) where purified tumour cells were analysed and individual telomere length distributions were significantly more homogeneous (mean standard deviation = 1Á28) compared to those observed in MM and MGUS patients (P < 0Á0001; MannWhitney). The telomere length heterogeneity in the MM samples was consistent with the differing replicative histories of the numerous cell populations that composed the unsorted bone marrow samples analysed. The majority of telomere length profiles derived from MM patient samples displayed multi-modal distributions with sub-populations of cells displaying more extensive telomere erosion (highlighted in red in Fig 1A) . To examine the telomere length distributions of purified myeloma plasma cell populations, we undertook cell sorting in a subset of myeloma bone marrow samples (n = 5) and analysed the CD138 + and CD138 -cell fractions separately. Distinct differences in the telomere length distributions were apparent ( Fig 1B) , with CD138 + plasma cells (mean = 2Á40 kb) displaying significant telomere erosion compared to the CD138 -cells (mean = 5Á26 kb; P = 0Á008). These data indicate that the shorter telomere length distribution observed in unsorted MM samples represent CD138 + malignant plasma cells.
Importantly these data are consistent with MM plasma cells exhibiting an extensive replicative history that is distinct to that of bone marrow CD138 -cells in these patients.
Overall, telomere length was shorter in MM compared to MGUS patient samples (P = 0Á017; Mann-Whitney) with 19% of MM samples within the fusogenic range ( Fig 1C) ; the telomere length threshold below which we detected telomere fusions in CLL (3Á81 kb) (Lin et al, 2014) . Telomere length declined as a function of age in MM at rates consistent with the extensive literature on telomere dynamics in normal peripheral blood samples (À25 bp/year, P = 0Á00056; Fig 1D) (Muezzinler et al, 2013) . However, there was no significant difference in telomere length between any of the International Staging System (ISS) subgroups (P = 0Á27; Fig 1C) or between sexes (P = 0Á22).
The median telomere length of the MM cohort provided modest prognostic resolution {HR = 1Á61 [95% confidence interval (CI), 1Á04-2Á53], P = 0Á03; data not shown}. In contrast, use of the previously determined telomere dysfunction threshold (Lin et al, 2014) was highly prognostic for overall survival in MM (HR = 3Á42 (95% CI, 3Á67-15Á81), P < 0Á0001; Fig 2A) ; a striking observation, given the variable contributions of plasma cells to the unsorted heterogeneous samples analysed.
Consistent with previous reports, the ISS provided strong prognostic information in our MM cohort (HR = 3Á56 (95% CI, 2Á92-9Á13), P < 0Á0001; Fig 2B) , which was similar to that derived using the telomere dysfunction threshold. In order to assess whether telomere length could add prognostic resolution to the ISS, we performed multivariate analysis on 113/131 (86Á3%) MM samples for which all relevant clinical data was available. In a model that included the potential covariates of mean telomere length, gender, age, ISS subgroups and the telomere dysfunction threshold (3Á81 kb), the most important prognostic factor was ISS, followed by age and telomere length below 3Á81 kb (Table SI) . After adjustment for ISS and age, telomere length <3Á81 kb was associated with significantly shorter survival (HR = 2Á23 (95% CI, 1Á26-3Á96), P = 0Á006; Fig 2C) . Despite the prognostic independence of telomere length, there was evidence of an interaction between ISS and this parameter, with the effect of short telomeres less prominent in patients with high-risk ISS score (P = 0Á05). However, in univariate analyses, stratified by ISS score, short telomeres still were associated with significantly worse survival in high-risk ISS patients (P = 0Á02). Overall, patients with good or standard risk ISS who manifested short telomeres, or high-risk ISS patients with long telomeres had intermediate survival when compared to concordant groups consisting of good/standard risk ISS and long telomeres and high-risk ISS and short telomeres (Fig 2D) . These findings suggest that a refinement of the risk classification could be obtained by incorporating telomere length Fig 2. Telomere length is highly prognostic in multiple myeloma (MM). Kaplan-Meier survival analysis was performed on the multiple myeloma (MM) cohort using the log-rank test (A) The telomere dysfunction threshold (<3Á81 kb) identified a subset of MM patients with inferior survival. (B) In keeping with previous reports, the International Staging System (ISS) 3 sub-group also showed significantly inferior survival compared to the combined ISS 1/2 sub-group. (C) Even after adjustment for ISS and age, MM patients with telomere length <3Á81 kb had significantly shorter survival. (D) The combination of ISS and the telomere dysfunction threshold provided a refinement of their prognostic information. ISS 1/2 patients with short telomeres, or ISS 3 patients with long telomeres had intermediate survival when compared to concordant groups consisting of ISS 1/2 and long telomeres and ISS 3 and short telomeres. 
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